WILX Home ·  Station Info
News  ·   Sports  ·   Weather  ·   Job Search  ·   Blogs  ·   Contests  ·   iWitness Photo/Video  ·   10toGo  ·   Instant Alert  ·   World News
Recipes · Restaurants · Community · School Closings · Lottery · Entertainment · Money · Breakroom · Apartment Guide · Repair Don’t Replace · Summer Guide
Health Information Update from the FDA
MRSA Concerns Save Email Print
Posted: 5:47 PM Oct 26, 2007
Last Updated: 5:47 PM Oct 26, 2007
Reporter: Jessica Aspiras
Email Address: jessica.aspiras@wilx.com

A | A | A

At random times throughout the year, parts of Ingham Regional Medical Center get cultured for Methicillin Resistant Staph Aureus or MRSA. The bacteria has been known to be in hospitals for more than forty years. But it's a relatively new strain that's causing concern for doctors -- a community acquired strain that, contains the toxin PVL.

"That makes it more virulent, in that, it can cause destruction of normal tissue. It can cause necrosis or dead tissue to form," explains Dr. Peter Gulick, Infectious Disease.

He says everyone has colonies of Staph Epi on their skin. While it's not harmful, MRSA can be. And now it's beginning to take on characteristics of Staph Epi -- primarily the ability to colonize on skin.

"Often times what happens is there's some break in the skin that allows the organism to get in and cause that skin infection," Ingham County Health Deptartment's Dr. Dean Sienko says.

MRSA, is resistant to drugs like penicillin and amoxicillin, but other antibiotics like tetracycline and bactrim are effective. Not only that, but as far as the bacteria's concerned, Dr. Gulick says, "Most people don't even know they've got it. They don't even know they're carrying it. Many times you can have it and not have any problems."

More Stories
Summer Remedies to Keep Kids Healthy and Happy Over the Holiday Weekend

Painkiller Safety

National Health Care Debate Hits Michigan

Babies Born Healthier

What's Going Around

One Woman's Fight With Kidney Disease

Obama Voicing Confidence on Health Care Changes

What's Going Around

Post Your Comments
First Name:
Location:
Enter Comments: characters left
Email (optional):
By posting this comment I have read and agree to the Terms of Use and Privacy Policy:
You must agree to the Terms of Service to continue.
CDC Data and Statistics Widget. Flash Player 9 is required.
MedWatch Safety Alerts from the FDA
  • Lantus (insulin glargine)
    FDA reviewing safety data regarding possible risk for cancer in patient with diabetes.
  • Varenicline (marketed as Chantix) and Bupropion (marketed as Zyban, Wellbutrin, and generics)
    FDA requires new Boxed Warnings and patient Medication Guides highlighting the risk of serious neuropsychiatric symptoms
  • Nestle Toll House Prepackaged, Refrigerated Cookie Dough
    FDA and the CDC are warning consumers not to eat any varieties of prepackaged Nestle Toll House refrigerated cookie dough due to the risk of contamination with E. coli O157:H7 (a bacterium that causes food borne illness). Since March 2009 there have been 66 reports of illness across 28 states. Twenty-five persons were hospitalized; 7 with a severe complication called Hemolytic Uremic Syndrome. No one has died.E. coli O157:H7 causes abdominal cramping, vomiting and a diarrheal illness, often with bloody stools. Most healthy adults can recover completely within a week. Young children and the elderly are at highest risk for developing HUS,which can lead to serious kidney damage and even death.
  • Stamina-Rx Dietary Supplement Products
    FDA and Hi-Tech Pharmaceuticals notified patients and healthcare professionals of a nationwide recall of all product sold under the name Stamina-Rx. Hi-Tech was notified by the FDA that the lab analysis of Stamina-Rx samples found that the product contained the undeclared ingredient − benzamidenafil − a Phosphodiesterase Type 5 inhibitor.
  • Cefepime (marketed as Maxipime) Update of Ongoing Safety Review
    FDA finished its analysis of a possible risk of higher death with cefepime and has determined that the data do not indicate a higher rate of death in cefepime-treated patients.